الفهرس 
Table of ContentsOnly 14 pages are availabe for public view
 |  | from | 183 |  |  |
| | | from | 183 | | |
Abstract
The impact of diabetes especially type 2 on public health is profound, as it has been shown to be major risk factor for many diseases, mainly cardiovascular diseases. The concept of Diabetic cardiomyopathy (DCM) was introduced for the first time by Rubler et al. (1972) depending on post-mortem observations noticed in diabetic patients with heart failure but with no coronary artery disease or other etiologies explaining heart failure. However, myocardial fibrosis with LV hypertrophy were observed in those patients. The aim of the present study was to investigate the role of EPO in rats with DCM and to study whether EPO is modulating cardiac dysfunctional changes seen in DCM. Further, the study tried to explore whether such modulatory effect is mediated through the antiapoptotic effect or the antioxidant effect and investigating the effect of EPO on other diabetic markers. The study involved fifty male Sprague dawley rats which were divided into five groups of 10 rats each. The rats of group Ⅰ served as normal control. group Ⅱ received HFD for 1month and asingle injection of STZ in a concentration of 35mg/kg intraperitoneal for induction of type 2 diabetes. group Ⅲ: (Diab + Gliben) diabetic rats treated with, Gliben at a dose (0.6 mg/kg daily by oral route) for 4 weeks, group Ⅳ: Diabetic rats treated with EPO; twice a week 4 weeks duration. (1000 IU/kg) and group Ⅴ: diabetic rats treated by both (EPO + Gliben) with the same previous doses for 4 weeks duration. In conclusion, it seems that chronic administration of EPO has exhibited a protective role against myocardial complications in a rat model of type 2 DM. Such protective role seems to be due to the antioxidant action of EPO as shown by the decline in oxidative marker MDA and enhancing the activity of GSH.